Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | International Journal of Clinical Oncology

International Journal of Clinical Oncology

International Journal of Clinical Oncology

Editor-in-Chief: Osamu Ogawa

ISSN: 1341-9625 (print version)
ISSN: 1437-7772 (electronic version)

Journal no. 10147

$99.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 6 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Instructions for Authors

Revised: October 29, 2015

Manuscript submission 

Legal requirements:

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Prerequisites for publication:

A copy of the certification form included in each issue must be submitted to the journal’s editorial office at the same time you submit your manuscripts via Editorial Manager.

Permissions:

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online submission:

Authors should submit their manuscripts to the International Journal of Clinical Oncology online. No manuscripts will be accepted by mail or fax. Please log in directly at: http://www.editorialmanager.com/ijco and upload your manuscript following the instructions given.

Potential conflict of interest  

Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. They should also state that they have full control of all primary data and that they agree to allow the journal to review their data if requested.
Therefore the manuscript must be accompanied by the "Conflict of Interest Disclosure Statement”. This form can be obtained from http://www.springer.com/10147/.
The corresponding author also should include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the "Conflict of Interest Disclosure Statement" forms.
IMPORTANT:
Upon receipt of the certification form and COI form, manuscripts are officially recognized as submissions

Manuscript preparation  

Types of articles:

Articles may be in the form of original articles, letters to the editor, review articles, and editorials.
  • Original articles should not exceed 3,000 words, not including the abstract, references, tables, and figure captions. The text should be arranged in accordance with the format described below in “Text”. Acceptance of an original article is based primarily on the originality of the work and its potential clinical influence. For reports of randomized controlled trials, authors should refer to the CONSORT statement of guidelines (http://www.consort-statement.org). For studies of the diagnostic accuracy of tests, authors are encouraged to refer to the STARD statement (http://www.stard-statement.org/).
  • Letters to the editor may offer criticism of published material. They must be objective, constructive, and educational, and should not exceed 500 words, not including references, tables, and figure captions.
  • Review articles provide an overview of the state of the art in an area or an update in an area of current interest in clinical oncology. They should be approximately 3,000 words not including the abstract, tables, figure captions, and have a maximum of 75 references.
  • Editorials may be published as viewpoints of the editor(s) of the journal on current, relevant topics.

Manuscript form:

The abstract, text, references, tables, and figure captions must be typed double-space with wide margins. Incomplete or improperly prepared manuscripts will be returned to the authors without review. A separate cover page should be provided. The abstract, text, acknowledgments, references, tables, captions, and figures should begin on separate sheets and follow in that order. Standard abbreviations and units should be used. Abbreviations should be defined at first appearance, and their use in the title and abstract should be avoided. Generic names of drugs and chemicals should be used.
All manuscripts must be written in English. Authors who are not fluent in English must seek the assistance of a colleague who is a native English speaker and is familiar with the field of the work.

Cover page:

The cover page should contain the title, the full names of the authors, and the street address of the authors’ academic affiliations. Please supply a fax number, telephone number, and e-mail address for the proofs.

Abstract:

The abstract should be comprehensible without reference to the text, and the use of abbreviations should be avoided whenever possible. The abstract should not exceed 250 words and should be arranged under the following subheadings for original articles: (1) Background (the problem being addressed and the purpose of the study); (2) Methods (study design/methods and materials); (3) Results (research findings), and (4) Conclusion(s) (summary of the main findings obtained and the conclusions drawn).

Key words:

3-6 key words should be listed below the abstract.

Text:

The text should be arranged as follows: (1) Introduction; (2) Patients and methods, or Materials and methods; (3) Results; (4) Discussion; (5) Acknowledgment(s). The sections should describe: (1) the problem being addressed and the purpose of the study with reference to previous findings; (2) materials and methods used in the study in concise yet sufficient detail to allow the study to be replicated; (3) main findings obtained; (4) conclusions drawn from the findings and implications for further research and clinical application, with a review of relevant published literature and other evidence.

Text formatting:

Manuscripts should be submitted in Word.
• Use a normal, plain font (e.g., 10-point Times Roman) for text.
• Use italics for emphasis.
• Use the automatic page numbering function to number the pages.
• Do not use field functions.
• Use tab stops or other commands for indents, not the space bar.
• Use the table function, not spreadsheets, to make tables.

Footnotes:

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables. Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols. Always use footnotes instead of endnotes.

References 

Citation:
Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].
Reference list
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list. The entries in the list should be numbered consecutively. Give the names of the first three authors only, followed by “et al” if there are other coauthors.
Journal article
1. Smith J, Jones M Jr, Houghton L, et al (1999) Future of health insurance. N Engl J Med 965:325–329
2. Inoue T, Sue K, Nakano K, et al. (1991) A case report of long survival in a 17-year-old girl with gastric carcinoma treated by immunochemo-endocrine therapy (in Japanese). Shinyaku to Rinsho (New Med) 40:117–121
Article by DOI
3. Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med (in press). doi: 10.1007/s001090000086
Book
4. South J, Blass B (2001) The future of modern genomics. Blackwell, London
Book chapter
5. Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp230-257
Online document
6. Doe J (1999) Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. Available via DIALOG. http://www.rsc.org/dose/title of subordinate document. Accessed Jan 1999
Dissertation
7. Trent JW (1975) Experimental acute renal failure. Dissertation, University of California
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see http://www.issn.org/2-22661-LTWA-online.php

Tables 

• All tables are to be numbered using Arabic numerals.
• Tables should always be cited in text in consecutive numerical order.
• For each table, please supply a table caption (title) explaining the components of the table.
• Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
• Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.

Figures 

Electronic Figure Submission:

• Supply all figures electronically.
• Indicate what graphics program was used to create the artwork.
• For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS Office files are also acceptable.
• Vector graphics containing fonts must have the fonts embedded in the files.
• Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.

Line art:

• Definition: Black and white graphic with no shading.
• Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
• All lines should be at least 0.1 mm (0.3 pt) wide.
• Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
• Vector graphics containing fonts must have the fonts embedded in the files

Halftone art:

• Definition: Photographs, drawings, or paintings with fine shading, etc.
• If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
• Halftones should have a minimum resolution of 300 dpi.

Combination art:

• Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
• Combination artwork should have a minimum resolution of 600 dpi.

Color art:

• Color art is free of charge for online publication.
• If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
• If the figures will be printed in black and white, do not refer to color in the captions.
• Color illustrations should be submitted as RGB (8 bits per channel).

Figure lettering:

• To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
• Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
• Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
• Avoid effects such as shading, outline letters, etc.
• Do not include titles or captions into your illustrations.

Figure numbering:

• All figures are to be numbered using Arabic numerals.
• Figures should always be cited in the text in consecutive numerical order.
• Figure parts should be denoted by lowercase letters (a, b, c, etc.). If illustrations are supplied with uppercase labeling, lowercase letters will still be used in the figure legends and citations.
• If an appendix appears in your article/chapter and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices (Electronic supplementary Material) should, however, be numbered separately.

Figure captions:

• Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
• Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
• No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
• Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
• Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure placement and size:

• When preparing your figures, size figures to fit in the column width.
• Figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
The publisher reserves the right to reduce or enlarge figures.

Accessibility:

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that
• All figures have descriptive captions (blind users could then use a text-tospeech software or a text-to-Braille hardware)
• Patterns are used instead or in addition to colors for conveying information (color-blind users would then be able to distinguish the visual elements)
• Any figure lettering has a contrast ratio of at least 4.5:1.

Electronic Supplementary Material 

Electronic supplementary material will be published in the online version only. It may consist of
・ Information that cannot be printed: animations, video clips, sound recordings
・ Ιnformation that is more convenient in electronic form: sequences, spectral data, etc.
・ Large original data, e.g. additional tables, illustrations, etc.

Submission:

・ Supply all supplementary material in standard file formats.
・ Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
・ To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

Audio, Video, and Animations:

Always use MPEG-1 (.mpg) format.

Text and Presentations:

・ Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
・ A collection of figures may also be combined in a PDF file.

Spreadsheets:

・ Spreadsheets should be converted to PDF if no interaction with the data is intended.
・ If the readers should be encouraged to make their own calculations, spreadsheets should be submitted as .xls files (MS Excel).

Specialized Formats:

Specialized formats such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files:

It is possible to collect multiple files in a .zip or .gz file.

Numbering:

• If any supplementary material is supplied, the text must make specific mention of the material as a citation, similar to that of figures and tables.
• Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
• Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.

Captions:

For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files:

Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

Accessibility:

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that
・ The manuscript contain a descriptive caption for each supplementary material
・ Video files do not contain anything that fl ashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

Permissions 

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

After acceptance 

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order Open Choice, offprints and printing of figures on offprints in color.
Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

Open Choice 

Open Choice allows you to publish open access in more than 1850 Springer Nature journals, making your research more visible and accessible immediately on publication.
Benefits:
  • Increased researcher engagement: Open Choice enables access by anyone with an internet connection, immediately on publication.
  • Higher visibility and impact: In Springer hybrid journals, OA articles are accessed 4 times more often on average, and cited 1.7 more times on average*.
  • Easy compliance with funder and institutional mandates: Many funders require open access publishing, and some take compliance into account when assessing future grant applications.
It is easy to find funding to support open access – please see our funding and support pages for more information.
*) Within the first three years of publication. Springer Nature hybrid journal OA impact analysis, 2018.

Copyright and license term – CC BY

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Open Choice publication:

In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink. We regret that Springer Open Choice cannot be ordered for published articles.
Springer Open Choice http://springer.com/openchoice
In cooperation with the Japan Society of Clinical Oncology and the publisher, one year after the date of print publication, articles will become publicly available through SpringerLink regardless of whether the Springer Open Choice option is chosen initially.

Copyright transfer:

Authors will be asked to transfer copyright of the article to the Japan Society of Clinical Oncology. This will ensure the widest possible protection and dissemination of information under copyright laws.

Offprints:

Offprints can be ordered by the corresponding author.

Color illustrations:

Publication of color illustrations is free of charge.

Proof reading:

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor. After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First:

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

Ethical Responsibilities of Authors 

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.
Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation can be achieved by following the rules of good scientific practice, which include:
  • The manuscript has not been submitted to more than one journal for simultaneous consideration.
  • The manuscript has not been published previously (partly or in full), unless the new work concerns an expansion of previous work (please provide transparency on the re-use of material to avoid the hint of text-recycling (“self-plagiarism”)).
  • A single study is not split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (e.g. “salami-publishing”).
  • No data have been fabricated or manipulated (including images) to support your conclusions
  • No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks are used for verbatim copying of material, and permissions are secured for material that is copyrighted.
    Important note: the journal may use software to screen for plagiarism.
  • Consent to submit has been received explicitly from all co-authors, as well as from the responsible authorities - tacitly or explicitly - at the institute/organization where the work has been carried out, before the work is submitted.
  • Authors whose names appear on the submission have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results.
  • Authors are strongly advised to ensure the correct author group, corresponding author, and order of authors at submission. Changes of authorship or in the order of authors are not accepted after acceptance of a manuscript.
  • Adding and/or deleting authors and/or changing the order of authors at revision stage may be justifiably warranted. A letter must accompany the revised manuscript to explain the reason for the change(s) and the contribution role(s) of the added and/or deleted author(s). Further documentation may be required to support your request.
  • Requests for addition or removal of authors as a result of authorship disputes after acceptance are honored after formal notification by the institute or independent body and/or when there is agreement between all authors.
  • Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential proprietary data is excluded.
If there is a suspicion of misconduct, the journal will carry out an investigation following the COPE guidelines. If, after investigation, the allegation seems to raise valid concerns, the accused author will be contacted and given an opportunity to address the issue. If misconduct has been established beyond reasonable doubt, this may result in the Editor-in-Chief’s implementation of the following measures, including, but not limited to:
  • If the article is still under consideration, it may be rejected and returned to the author.
  • If the article has already been published online, depending on the nature and severity of the infraction, either an erratum will be placed with the article or in severe cases complete retraction of the article will occur. The reason must be given in the published erratum or retraction note. Please note that retraction means that the paper is maintained on the platform, watermarked "retracted" and explanation for the retraction is provided in a note linked to the watermarked article.
  • The author’s institution may be informed.

For authors and editors


  • Journal Citation Reports®
    2017 Impact Factor
  • 2.610
  • Aims and Scope

    Aims and Scope

    Close

    The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for authors

    Instructions for Authors

    Close

  • Certification Form (pdf, 81 kB)
  • Conflict of Interest Disclosure Statemen...
  • English Language Editing

    English Language Editing

    Close

  • Author Academy: Training for Authors
  • Copyright Information

    Copyright Information

    Close

    Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher, and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the Japan Society of Clinical Oncology.

    The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
    While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    Special regulations for photocopies

    To photocopy any work from this publication, permission must be obtained from the following organization, which has been delegated by the copyright owner for copyright clearance (expect in the USA, for which, see below): Japan Academic Association for Copyright Clearance (JAACC), 6-41 Akasaka 9-chome, Minato-ku, Tokyo 107-0052, Japan. Telephone: +81-3-3475-5618; Fax: +81-3-3475-5619; E-mail: jaacc@mtd.biglobe.ne.jp. In the USA: Photocopies may be made for personal or in-house use beyond the limitations stipulated under Section 107 or 108 of US. Copyright Law, provided a fee is paid. All fees should be paid to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA, Telephone: +1-978-750-8400; Fax: +1-978-646-8600, stating the ISSN number, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the society.

    © The Japan Society of Clinical Oncology

Services for the Journal

Alerts for this journal

 

Get the table of contents of every new issue published in International Journal of Clinical Oncology.